

**Research**

## **Analytical Method Development and Validation of Thioridazine by RP-HPLC method**

**Rucha M. Chopade<sup>1</sup>, Priyanka S. Patil<sup>2</sup>, Nikita U. Dhake<sup>1</sup>, Mohini V. Kshirsagar<sup>2</sup>,  
Vaishnavi R. Mankar<sup>3</sup>, Pranita A. Thakre<sup>3</sup>, Vinayak M. Shejol<sup>3</sup>**

<sup>1</sup>Gulabrao Deokar Institute of Pharmacy and Research Centre Jalgaon, Maharashtra, India.

<sup>2</sup>Dr Rajendra Gode College of Pharmacy Malkapur, Maharashtra, India.

<sup>3</sup>NK College of Pharmacy, Antraj, Khamgaon, Maharashtra, India

---

Received: 10-08-2024 / Revised: 23-10-2024 / Accepted: 05-11-2024

Corresponding Author: Vinayak M. Shejol

Email: vinayakshejol10@gmail.com

Conflict of interest: Nil

---

**Abstract:**

Method development and validation are extremely important in the development of drug material. For many drug products, Scientists working on Investigational New Drug (IND), New Drug Application (NDA), and Abbreviated New Drug Application (ANDA) used to characterized API'S and excipients have not been sufficiently developed or validated <sup>1,2</sup>. The objective of the present study is to establish and generate inheriting Validation data for Thioridazine RP-HPLC method.

**Keywords:** Thioridazine, RP-HPLC, Validation.

---

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

---

**Introduction:**

Thioridazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; blocks alpha-adrenergic effect, depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. This work was planned on the conventional lines of procedure in the development of analytical method for Thioridazine in single component formulation. Also, validating accuracy of developed method as per ICH guidelines.

**Materials and Method:**

**Selection of Analytical Technique<sup>3</sup>**

HPLC was selected as analytical technique for estimation of Thioridazine

**Instruments:** The analysis of the drug was carried out on Younglin (S.K.) Gradient System UV Detector. Equipped with Reverse Phase (Cosmosil) C18 column (4.6 id x 250mm; 5µm), a SP930D pump, a 20µ l injection loop and UV630D Absorbance detector and running autochro-3000 software.

**a) Selection of stationary phase:** The column used in this method C18 Cosmosil. The configuration of the column is 4.6 x 250 mm, particle size 5 µm. C18 column gives high non polar retentivity, symmetric peak shape, highly reproducible and stable ideal for HPLC method

**b) Solubility Studies:** This study was carried out to find an ideal solvent in which drugs are completely soluble. Various solvents were tried for checking solubility of Thioridazine. From solubility studies it was concluded

that of Thioridazine is soluble in Methanol and water however it is soluble in Water PH adjusted 0.1% Orthophosphoric Acid with TEA, Buffer pH 3.0.

**c) Chromatographic conditions:** The following chromatographic conditions were established by trial and error and were kept constant throughout the experimentation.

**List of Mobile Phase :**

1. ACN+Methanol+0.05% (OPA with TEA)Water (10+30+60% v/v) 239 nm 0.7ml/min
2. ACN+Methanol+0.05% (OPA with TEA)Water (25+25+50% v/v) 239 nm 0.7ml/min
3. ACN+ 0.1% (OPA with TEA)Water (70+30 % v/v) 239 nm 0.7ml/min
4. ACN+ 0.05% (OPA with TEA)Water (70+30 % v/v) 239 nm 0.8ml/min
5. MEOH+ 0.05% (OPA with TEA)Water (60+40 % v/v) 239 nm 0.7ml/min
6. MEOH+ 0.05% (OPA with TEA)Water (70+30 % v/v) 239 nm 0.7ml/min

**Preparation of Stock Standard Solution <sup>4</sup>:**

**Standard Solution Stock I : (Thioridazine )**

Accurately weight and transfer 10mg Thioridazine working standard into 10 ml volumetric flask as about diluent Methanol completely and make volume up to the mark with the same solvent to get 1000µg/ml standard (stock solution) and 15 min sonicate to dissolve it and the resulting stock solution 0.1ml was transferred to 10 ml volumetric flask and the volume was made up to the mark with mobile phase Methanol : Water (0.1%OPA with TEA)Water, prepared in (70ml MEOH : 30ml WATER v/v) solvent.

**Validation of method for analysis of Thioridazine:**

The developed method was validated as per ICH guidelines.

**Analytical Method validation** Analytical method validation was carried out as per ICH method validation guidelines Q2 (R1).

**Linearity:**

Linearity of an analytical method is its ability to elicit test results that are directly or by a well defined mathematical transformation, proportional to the concentration of analyte in samples within a given range.

**Determination:**

The linearity of the analytical method is determined by mathematical treatment of test results obtained by analysis of samples with analyte concentrations across the claimed range. Area is plotted graphically as a function of analyte concentration. Percentage curve fittings are calculated.

**Preparation of standard stock solution for linearity:**

Average weight of tablet sample (equivalent to 10 mg of Thioridazine were weighed and transferred to 10 mL volumetric flask & diluent was added to make up the volume. Sonicated for 10 min with occasional swirling. 0.1 ml of this solution diluted upto 10 ml volumetric flask with diluents was added to make up the volume.

**Table1 : Table for linearity**

| Sr No. | Concentration (µg/mL) |
|--------|-----------------------|
| 1      | 10                    |
| 2      | 20                    |
| 3      | 30                    |
| 4      | 40                    |
| 5      | 50                    |

**Accuracy (recovery)<sup>5</sup>:**

The accuracy of an analytical method is the closeness of test results obtained by that method to the true value. Accuracy may often be expressed as percent recovery by the assay of known added amounts of analyte. The accuracy of an analytical method is determined by applying the method to analyzed samples, to which known amounts of analyte have been added. The accuracy is calculated from the test results as the percentage of analyte recovered by the assay.

**Preparation of standard stock solution:**

10 mg of Thioridazine working standards were weighed and transferred to 10 mL volumetric flask & diluent was added to make up the volume 0.2ml of this solution diluted upto 10 ml with diluent.

**Application of proposed method for analysis of tablet formulation:**

**Accuracy**


The accuracy was determined by Thioridazine (equivalent to 10 mg of Thioridazine ) (80%, 100 % and 120 % of the label claimed, respectively) to quantity equivalent to average weight of marketed tablets. This powder mixture containing 10 mg of Thioridazine were triturated and then subjected to chromatographic analysis using the described method. The resulting mixtures were analyzed in triplicates over three days. The % recovery of added drug was taken as a measure of accuracy.

**Table2: Table for accuracy**

| Sample        | Amount added (mg) |
|---------------|-------------------|
| Accuracy 80%  | 8                 |
| Accuracy 100% | 10                |
| Accuracy 120% | 12                |

**Results and discussion:**

**Chromatogram of Trial 1:**




**Fig No 1: Chromatogram of Trial 1**

**Table No 3: Result for Chromatogram of Trial 1**

| No. | RT [min ] | Area [mV*s] | Area%  | TP    | TF   | Resolution |
|-----|-----------|-------------|--------|-------|------|------------|
| Sum | 5.4933    | 1093.0880   | 100.00 | 900.4 | 1.45 | 0.000      |

**Chromatogram of Trial 2:**




**Fig No 2 : Chromatogram of Trial 2**

**Table No .4: Result for Chromatogram of Trial 2**

| No. | RT[mi<br>n] | Area[mV*s<br>] | Area%  | TP    | TF     | Resolution |
|-----|-------------|----------------|--------|-------|--------|------------|
| 1   | 3.8667      | 3604.02        | 0.51   | 649.5 | 1.3146 | 0.0000     |
| 2   | 4.5167      | 6975.5645      | 100.00 | 297.3 | 3.7266 | 0.7856     |
| Sum |             | 7011.6045      |        |       |        |            |

**Chromatogram of Trial 3:**




**Fig No 3 : Chromatogram of Trial 3**

**Table No .5: Result for Chromatogram of Trial 3**

| No. | RT[ <b>min</b> ] | Area[mV*<br>s] | Area%  | TP     | TF     | Resolution |
|-----|------------------|----------------|--------|--------|--------|------------|
| 1   | 3.0500           | 9977.7949      | 100.00 | 3718.4 | 1.9508 | 0.0000     |
| Sum |                  | 9977.7949      |        |        |        |            |

**Chromatogram of Trial 4:**



**Fig No 4: Chromatogram of Trial 4**

**Table No .6: Result for Chromatogram of Trial 4**

| No. | RT[min] | Area[mV*s] | Area% | TP      | TF     | Resolution |
|-----|---------|------------|-------|---------|--------|------------|
| 1   | 2.7833  | 3468.4341  | 100.0 | 2892.01 | 1.5317 | 0.0000     |
| Sum |         | 3171.7716  |       |         |        |            |

Chromatogram of Trial 5:




Fig No 5: Chromatogram of Trial 5

Table No .7: Result for Chromatogram of Trial 5

| No. | RT[min] | Area[mV*s] | Area% | TP     | TF     | Resolution |
|-----|---------|------------|-------|--------|--------|------------|
| 1   | 2.8667  | 3609.9768  | 99.13 | 3060.6 | 1.5317 | 0.0000     |
| 2   | 3.8833  | 31.6388    | 0.87  | 228.5  | 4.0387 | 1.6466     |
| Sum |         | 3641.6157  |       |        |        |            |

Chromatogram of Trial 6:




Fig No 6: Chromatogram of Trial 6

Table No .8: Result for Chromatogram of Trial 6

| No. | RT[min] | Area[mV*s] | Area% | TP      | TF     | Resolution |
|-----|---------|------------|-------|---------|--------|------------|
| 1   | 4.5867  | 2291.8047  | 100.0 | 11609.4 | 1.1004 | 0.0000     |
| Sum |         | 2291.8047  |       |         |        |            |

The final chromatographic conditions selected were as follow:

Analytical column : Cosmosil C18 Column (250mm x 4.6mm, 5µ m partical size).

Injection volume : 20µl


Flow rate : 0.7ml/min

Mobile phase : Methanol : water (70: 30% V/V)

Detection : 239 nm

Run Time : 15 min

**Preparation of Standard chromatogram of Thioridazine**




**Fig No.7: Chromatogram of standard Thioridazine**

**Table No 9: Result for standard Chromatogram of Thioridazine**


| No. | RT[min] | Area[mV*s] | Area%  | TP      | TF     | Resolution |
|-----|---------|------------|--------|---------|--------|------------|
| 1   | 4.600   | 2169.0204  | 100.00 | 13719.6 | 1.1438 | 0.0000     |
| Sum |         | 2169.0204  |        |         |        |            |

**Analytical of Method Validation:**

- Linearity:** From Thioridazine standard stock solution, different working standard solution (10-50µg/ml) were prepared in mobile phase 20 µl of sample solution was injected into the chromatographic system using mixed volume loop injector Chromatograms were recorded.



**Fig.No.8 .Chromatogram of linearity 10 MCG**



**Fig.No.9 .Chromatogram of linearity 20 MCG**




Fig.No.10 .Chromatogram of linearity 30 MCG




Fig.No.11 .Chromatogram of linearity 40 MCG




Fig.No.12 .Chromatogram of linearity 50 MCG

Table No 10. Linearity of Thioridazine

| S. No. | Conc. (Mcg/ml) | Area Thioridazine |
|--------|----------------|-------------------|
| 1      | 10             | 567.94            |
| 2      | 20             | 1034.08           |
| 3      | 30             | 1583.81           |
| 4      | 40             | 2164.20           |
| 5      | 50             | 2771.86           |

**Regression equation data for Thioridazine**

Regression Equation Data  $Y=mx+c$

Slope(m) 55.38x , Intercept(c) 37.01 , Correlation Coefficient 0.997

**Accuracy:-** Recovery studies were performed to validate the accuracy of developed method. To pre analyzed tablet solution, a definite concentration of standard drug (80%, 100%, and 120%) was added and then its recovery was analyzed




Fig.13. Chromatogram of Accuracy 80%

Accuracy 100%




Fig.14. Chromatogram of Accuracy 100%

Accuracy 120%




Fig.15. Chromatogram of Accuracy 120%

**Conclusion:**

Simple, rapid, accurate and precise RP-HPLC have been developed and validated for the routine analysis of Thioridazine in API and tablet dosage forms. Both methods are suitable for the simultaneous determination of Thioridazine in Single-component formulations without interference of each other. The developed methods are recommended for routine and quality control analysis of the investigated drugs in two component pharmaceutical preparations. The amount found from the proposed methods was in good agreement with the label claim of the formulation. Also the value of standard deviation and coefficient of variation calculated were satisfactorily low, indicating the suitability of the proposed methods for the routine estimation of tablet dosage forms.

**References:**

1. E. Katz, Quantitative Analysis Using Chromatographic Techniques, Wiley India Pvt. Ltd.: 2009, pp. 193 -211.
2. P. D. Sethi, HPTLC: Quantitative Analysis of Pharmaceutical formulation, 1stedn., CBS Publications, New Delhi, 1996, pp.162-165.
3. Khan H. Analytical method development in pharmaceutical research: steps involved in HPLC method development. Asian Journal of Pharmaceutical Research. 2017;7(3):203-7.
4. Chebrolu KK, Jayaprakasha GK, Yoo KS, Jifon JL, Patil BS. An improved sample preparation method for quantification of ascorbic acid and dehydroascorbic acid by HPLC. LWT. 2012 Jul 1;47(2):443-9.
5. Betz JM, Brown PN, Roman MC. Accuracy, precision, and reliability of chemical measurements in natural products research. Fitoterapia. 2011 Jan 1;82(1):44-52.

\*\*\*\*\*